{
  "id": 17865142,
  "title": "Earnings call transcript: Bioventus Q3 2026 revenue miss sparks sharp selloff",
  "url": "https://urgent.news/2026/11/02/earnings-call-transcript-bioventus-q3-2026-revenue-miss-sparks-sharp",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-02T22:13:08.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-bioventus-q3-2026-revenue-miss-sparks-sharp-selloff-93CH-4993035"
  },
  "original_language": "en",
  "account": "Bioventus reported a Q3 2026 adjusted earnings of $0.17 a share, exceeding Wall Street's forecast of $0.16, but revenue of $142.4 million lagged behind the $149.51 million consensus. The mixed disclosure prompted a sharp 18.78% drop in shares to $10.681 in after-hours trading from the regular session's $13.15 close. Management also revised full-year revenue guidance to $590 million to $595 million, down from the prior midpoint of about $12 million higher. While adjusted EPS was 6.25% higher than expected, revenue fell short by $7.11 million or 4.76%. The earnings beat was modest, but the revenue shortfall was more significant, as investors often prioritize sales momentum when assessing growth.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}